Rare disease, oncology and auto-immune biotechnology company, Nandi Life Sciences LLC, was this month voted by investors as #3 in the Top 10 “Most Promising” early stage life science companies at the prestigious Texas Life Science Forum, the leading life science conference in Texas, USA.
Nandi is an immuno-oncology biotech working with scientific founders, backed by Texas Medical Center Innovation, and enrolled in the elite Accelerator for Cancer Therapeutics, which is within the same ecosystem as MD Anderson Cancer Center, the number one cancer research center in the US.
According to Nandi co-Founder, Dr. Sophie Chandauka MBE: “Last month I announced that my brother Dr. Tinashe Chandauka and I have launched a biotech – Nandi Life Sciences LLC. The combination of Tinashe’s sciences background and my corporate finance and operations experience positions us to uniquely support scientific founders who often do not have commercialiSation expertise and lack the confidence to navigate company creation.
“Nandi’s purpose is to help scientific founders to bring to market ground-breaking technologies that address unmet medical needs of patients, whilst creating lasting value for other stakeholders.
“Our mission requires us to inspire scientific founders to take big risks to develop therapeutics that can be commercialiSed to address complex diseases that often disproportionately impact women and racial minorities.
“Our vision… is a world in which scientists win the battle against rare diseases, starting with cancer.”